Skip to main content
HR 3666 114th Congress House Health Congressional oversight Department of Health and Human Services Executive agency funding and structure Immunology and vaccination Medical research Musculoskeletal and skin diseases National Institutes of Health (NIH) Research administration and funding

Scleroderma and Fibrosis Research Enhancement Act of 2015

Introduced: October 1, 2015 See on congress.gov
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 2, 2015
Referred to the Subcommittee on Health.
Oct 1, 2015
Referred to the House Committee on Energy and Commerce.
Oct 1, 2015
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Scleroderma and Fibrosis Research Enhancement Act of 2015

This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)

The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.

The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.

The commission must be terminated not later than two years after establishment.

The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.
What's happening now October 2, 2015

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015. 114th Congress. Open America. https://openamerica.io/bill/114-HR-3666/
MLA
"H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-HR-3666/.
Bluebook (legal)
H.R. 3666, 114th Cong. (2026), https://openamerica.io/bill/114-HR-3666/.
Markdown link
[H.R. 3666: Scleroderma and Fibrosis Research Enhancement Act of 2015](https://openamerica.io/bill/114-HR-3666/)
Report a problem